CClinicalTrials.gg
RecruitingNCT05164107PULSE-EUUpdated Jan 30, 2026

Safety and Performance of a Pulsed Field Device for Global Mapping and Ablation of the Left Atrium for the Treatment of Atrial Fibrillation

An interventional study of Globe Mapping and Pulsed Field Ablation System (Globe PF System) in Atrial Fibrillation, sponsored by Kardium Inc.. Recruiting at 1 site in Czechia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Kardium Inc. · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
175
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to provide clinical data pertaining to the safety and performance of the Globe Mapping and Pulsed Field Ablation System for treating subjects with atrial fibrillation (AF).

02

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Globe Mapping and Ablation System
  • Atrial Fibrillation
  • Pulsed Field Ablation
03

In context

Atrial Fibrillation

3,870 studies on the registry are indexed under Atrial Fibrillation; 924 are open to participants now.

This study's planned enrollment of 175 is above the median of 144 across 2,380 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

Kardium Inc. is the lead sponsor of 10 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Subjects planned for an AF catheter ablation procedure, with a documented history of AF.

    1. Diagnosis must be confirmed within 12 months before enrollment.
    2. (Repeat ablations) Patient had 1 previous PVI procedure with cryoablation, radiofrequency ablation or pulsed field ablation
  2. Subjects between 18 and 75 years of age, inclusive

Key Exclusion Criteria:

  1. Patients who have contraindications to open heart surgery
  2. Patients from an Intensive Care Unit
  3. Patients with active systemic infection (sepsis)
  4. Patients who have had previous ablation in the left or right atrium
  5. Patients who are post-heart transplant or who are awaiting cardiac transplantation or other cardiac surgery
  6. Patients with cardiac implants that may interfere with device delivery or positioning (e.g. atrial septal defect closure device, left atrial appendage occluder)
  7. Patients with mitral valve prolapse or other heart valve abnormalities excepting mild to moderate mitral regurgitation
  8. Patients with New York Heart Association Class III or IV heart failure
  9. History of a documented thromboembolic event, including stroke or transient ischemic attack (TIA)
  10. Bleeding disorder history
  11. Patients with a known sensitivity to anesthesia or neuromuscular block agent
  12. Currently undergoing long-term treatment with steroids, not including intermittent use of inhaled steroids for respiratory disease
  13. Myocardial infarction within the last three months
  14. Atrioventricular (AV) block II° or III°
  15. Left ventricular ejection fraction (LVEF) of less than 35%
  16. Unstable angina
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
175 participants (estimated)

Study arms

  • Experimental
    Globe Mapping and Pulsed Field Ablation System

    Device: Globe Mapping and Pulsed Field Ablation System (Globe PF System)

Interventions

  • DeviceGlobe Mapping and Pulsed Field Ablation System (Globe PF System)

    During the procedure, the Globe Catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the left atrium (LA) will be followed by pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI). Additional PFA or radiofrequency (RF) ablation lesions may be created as deemed appropriate by the Investigator. Intracardiac electrogram mapping with the Globe PF System will be used to confirm PVI.

06

What researchers measure

Primary outcomes

  1. Rate of subjects presenting with primary safety events which are device- or procedure-related

    Time frame: up to 3-month visit

07

Study locations

1 of 1 sites recruiting
  • Motol and Homolka University Hospital
    Prague, 150 00, Czechia
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05164107
Lead sponsor
Kardium Inc.
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
Dec 8, 2021
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jan 30, 2026

Study contacts

Clinical Affairs
Contact
Clinical.Affairs@kardium.com
+1 (604) 248 8891
Motol and Homolka University Hospital
principal investigator · V Úvalu 84/1, 150 00 Prague 5, Czech Republic

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion